

A Public Limited Company with Share Capital of 12,683,913.25 euros
Registered Address 49, boulevard du Général Martial Valin – 75015 Paris
Paris Trade and Companies' Register 410 910 095

SUMMARY OF ONXEO'S LIQUIDITY CONTRACT WITH KEPLER CHEUVREUX

January 6, 2020 – 5:45 pm CET

Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, the following resources were listed in the liquidity account as at December 31, 2019, settlement date:

- 341,069 shares
- €13,897.05 in cash

During the 2nd half of 2019, were negotiated a total of:

BUY	510,522 shares	€327,615.49	656 executions
SALE	380,311 shares	€246,522.48	525 executions

It is recalled that for the last half-year summary as at June 30, 2019, the following resources were included in the liquidity account:

- 210,858 shares
- €95,092.53 in cash

During the 1st half of 2019, were negotiated a total of:

BUY	551,475 shares	€486,463.73	866 executions
SALE	451,712 shares	€404,963.46	711 executions

It is also recalled that when the contract was set up on December 3, 2018, the following resources had been allocated to the liquidity account:

- 87,612 shares
- €196,423.24 in cash

The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.



About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON™ is Onxeo's proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company's product pipeline.

AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

Onxeo's portfolio also includes **belinostat**, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US under the name Beleodaq® (belinostat IV form).

For further information, please visit www.onxeo.com.

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.7.1.4 "Risk Factors" ("*Facteurs de Risque*") of the 2018 registration document filed with the *Autorité des marchés financiers* on April 25, 2019 under number D.19-0282, which is available on the *Autorité des marchés financiers* website (www.amf-france.org) or on the Company's website (www.onxeo.com).

Onxeo

Valerie Leroy,
Investor Relations
investors@onxeo.com
+33 1 45 58 76 00

Media Relations

Nicolas Merigeau
NewCap
onxeo@newcap.eu
+33 1 44 71 94 98

Investor Relations / Strategic Communication

Dušan Orešanský / Emmanuel Huynh
NewCap
onxeo@newcap.eu
+33 1 44 71 94 92

Investor Relations US

Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
+1 212 915 2578



APPENDIX

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	656	510,522	327,615.49	525	380,311	246,522.48
01/07/2019	4	4,000	3,160.00	42	28,493	22,794.40
02/07/2019	3	2,000	1,580.00	3	2,001	1,620.81
08/07/2019	4	3,000	2,370.00	-	-	-
09/07/2019	8	6,001	4,680.78	1	1	0.79
10/07/2019	6	5,000	3,850.00	-	-	-
11/07/2019	2	1,001	770.77	4	2,001	1,560.78
12/07/2019	5	4,250	3,272.50	2	1,004	783.12
15/07/2019	3	751	578.27	1	1	0.77
16/07/2019	2	2,000	1,520.00	1	749	576.73
18/07/2019	22	17,296	12,972.00	1	1	0.76
19/07/2019	4	1,705	1,261.70	2	275	206.25
22/07/2019	11	9,000	6,570.00	1	1	0.73
23/07/2019	6	5,922	4,204.62	18	9,999	7,299.27
24/07/2019	3	2,000	1,460.00	5	2,422	1,792.28
25/07/2019	2	958	728.08	29	22,304	16,951.04
26/07/2019	20	16,043	12,032.25	-	-	-
29/07/2019	2	1,000	740.00	-	-	-
30/07/2019	4	3,001	2,190.73	1	1	0.74
01/08/2019	9	6,000	4,320.00	-	-	-
02/08/2019	4	2,078	1,475.38	-	-	-
05/08/2019	14	12,000	8,520.00	2	1,000	710.00
06/08/2019	1	144	100.80	2	1,000	710.00
07/08/2019	7	6,856	4,799.20	-	-	-
08/08/2019	11	4,000	2,800.00	-	-	-
09/08/2019	18	29,001	20,300.70	16	19,850	14,292.00
12/08/2019	11	9,946	6,862.74	3	3,000	2,100.00
13/08/2019	21	16,317	11,095.56	14	9,047	6,332.90
14/08/2019	23	18,738	12,929.22	28	19,155	13,600.05
15/08/2019	22	24,000	15,840.00	-	-	-
16/08/2019	2	2,000	1,300.00	12	10,000	6,700.00
19/08/2019	-	-	-	8	7,000	4,760.00



PRESS RELEASE

20/08/2019	1	491	333.88	5	4,000	2,760.00
21/08/2019	5	4,000	2,760.00	5	4,000	2,800.00
22/08/2019	5	3,509	2,386.12	-	-	-
23/08/2019	7	5,001	3,350.67	4	2,201	1,496.68
26/08/2019	2	1,000	670.00	-	-	-
27/08/2019	2	186	124.62	1	1	0.67
28/08/2019	1	1	0.68	1	1	0.68
29/08/2019	11	6,125	4,042.50	-	-	-
30/08/2019	6	2,690	1,748.50	-	-	-
02/09/2019	3	3,000	1,980.00	11	7,015	4,700.05
03/09/2019	8	4,355	2,874.30	-	-	-
04/09/2019	2	645	419.25	-	-	-
05/09/2019	1	1,000	650.00	-	-	-
06/09/2019	3	2,001	1,300.65	1	1	0.65
09/09/2019	6	3,000	1,920.00	-	-	-
10/09/2019	6	6,000	3,840.00	12	9,000	5,940.00
11/09/2019	6	4,000	2,560.00	-	-	-
12/09/2019	17	22,999	14,259.38	-	-	-
13/09/2019	-	-	-	7	5,000	3,150.00
16/09/2019	-	-	-	1	1,000	630.00
17/09/2019	11	9,245	5,824.35	6	5,374	3,439.36
18/09/2019	12	6,755	4,188.10	5	4,000	2,520.00
19/09/2019	4	3,000	1,950.00	35	30,411	20,375.37
20/09/2019	18	15,000	9,450.00	-	-	-
23/09/2019	5	5,000	3,100.00	-	-	-
24/09/2019	1	1,000	610.00	-	-	-
25/09/2019	4	3,000	1,830.00	-	-	-
26/09/2019	1	81	49.41	-	-	-
27/09/2019	7	4,920	3,001.20	1	1	0.61
30/09/2019	1	1,000	600.00	2	1,254	777.48
01/10/2019	2	6,000	3,600.00	1	746	462.52
02/10/2019	2	2,000	1,200.00	-	-	-
03/10/2019	7	9,000	5,310.00	-	-	-
04/10/2019	2	1,592	923.36	-	-	-
07/10/2019	4	2,408	1,348.48	-	-	-
08/10/2019	1	1,000	540.00	-	-	-
09/10/2019	1	1	0.54	1	1	0.54
10/10/2019	1	1,000	530.00	-	-	-



PRESS RELEASE

11/10/2019	1	1,000	520.00	-	-	-
14/10/2019	3	2,000	1,000.00	-	-	-
15/10/2019	-	-	-	8	7,000	3,920.00
16/10/2019	-	-	-	14	12,000	7,200.00
17/10/2019	1	2,000	1,160.00	-	-	-
18/10/2019	1	1,000	560.00	-	-	-
21/10/2019	21	14,000	7,840.00	1	1,000	560.00
22/10/2019	1	1	0.55	1	1	0.55
23/10/2019	-	-	-	13	13,000	7,410.00
24/10/2019	13	8,301	4,648.56	2	376	214.32
25/10/2019	10	3,700	1,998.00	-	-	-
28/10/2019	2	2,000	1,080.00	-	-	-
29/10/2019	1	1	0.54	1	1	0.54
30/10/2019	-	-	-	1	1,000	550.00
31/10/2019	5	2,001	1,060.53	1	1	0.55
01/11/2019	3	2,001	1,040.52	5	3,672	1,982.88
04/11/2019	-	-	-	5	1,329	717.66
05/11/2019	3	3,000	1,650.00	5	4,000	2,240.00
06/11/2019	6	5,000	2,750.00	8	6,625	3,710.00
07/11/2019	6	3,000	1,650.00	2	1,001	560.56
08/11/2019	-	-	-	3	999	559.44
11/11/2019	1	1,000	550.00	1	1	0.56
12/11/2019	2	2,000	1,100.00	2	1,999	1,119.44
13/11/2019	8	6,000	3,300.00	10	7,963	4,459.28
14/11/2019	13	9,525	5,524.50	44	31,528	18,601.52
15/11/2019	18	14,475	8,250.75	-	-	-
18/11/2019	2	2,000	1,120.00	-	-	-
19/11/2019	14	8,152	4,646.64	15	15,000	8,700.00
20/11/2019	10	6,848	3,834.88	1	1,000	560.00
21/11/2019	3	3,000	1,650.00	1	1,000	570.00
22/11/2019	2	2,000	1,100.00	7	3,000	1,650.00
25/11/2019	2	2,000	1,100.00	8	2,545	1,425.20
26/11/2019	8	4,454	2,449.70	5	3,455	1,934.80
27/11/2019	4	1,929	1,060.95	1	1	0.56
28/11/2019	1	1	0.55	3	2,001	1,120.56
29/11/2019	6	4,100	2,255.00	1	500	275.00
02/12/2019	3	2,517	1,359.18	-	-	-
03/12/2019	1	1	0.53	1	1	0.53



PRESS RELEASE

04/12/2019	12	5,001	2,650.53	1	1	0.53
05/12/2019	3	2,000	1,040.00	5	2,500	1,325.00
06/12/2019	1	500	265.00	4	4,000	2,160.00
09/12/2019	6	3,605	1,910.65	1	1	0.55
10/12/2019	2	1,395	725.40	-	-	-
11/12/2019	1	1	0.52	1	1	0.52
12/12/2019	8	5,463	2,950.02	19	15,588	8,573.40
13/12/2019	3	3,000	1,620.00	-	-	-
16/12/2019	3	2,489	1,344.06	-	-	-
17/12/2019	5	3,168	1,679.04	-	-	-
18/12/2019	2	1,880	977.60	-	-	-
19/12/2019	-	-	-	2	1,000	540.00
23/12/2019	2	2,000	1,040.00	-	-	-
27/12/2019	1	1,000	510.00	-	-	-
30/12/2019	-	-	-	1	1,000	530.00
31/12/2019	2	2,000	1,080.00	26	20,910	11,500.50